Navigation

Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) [ID538]

Everolimus in combination with an aromatase inhibitor for the treatment of HER2 negative, oestrogen receptor positive locally advanced or metastatic breast cancer after prior endocrine therapy

Status: History
Expected date of issue: July 2013
Referral date: July 2012
Process: STA
Notes:

Scoped as part of Batch 23

Topic area:
 

NICE project team

Executive Lead: Carole Longson
Technical Lead: Martyn Burke
Communications manager: Laura Gibson
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 22 November 2012
1st appraisal committee meeting: 20 February 2013
2nd appraisal committee meeting 22 May 2013
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Novartis Pharmaceuticals UK (everolimus)

Patient/carer groups

  • Breakthrough Breast Cancer
  • Breast Cancer Care

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Possible comparator manufacturers

  • Actavis (docetaxel, exemestane, gemcitabine, paclitaxel, tamoxifen, vinorelbine) (not participating)
  • Arrow Generics (tamoxifen) (not participating)
  • AstraZeneca (fulvestrant) (not participating)
  • Bristol-Myers Squibb Pharmaceuticals  (paclitaxel)
  • Celgene (paclitaxel albumin) (not participating)
  • Eli Lilly (gemcitabine) (not participating)
  • Hospira  (docetaxel, gemcitabine, paclitaxel, vinorelbine) (not participating)
  • Kent Pharmaceuticals (tamoxifen) (not participating)
  • Medac UK  (docetaxel, gemcitabine, paclitaxel, vinorelbine) (not participating)
  • Mylan Pharmaceuticals (gemcitabine, tamoxifen) (not participating)
  • Pfizer (exemestane, tamoxifen)
  • Pierre Fabre (vinorelbine)
  • Roche Products (capecitabine)
  • Rosemont Pharmaceuticals (tamoxifen) (not participating)
  • Sandoz (gemcitabine, paclitaxel, tamoxifen, vinorelbine) (not participating)
  • Sanofi-aventis (docetaxel) (not participating)
  • Sun pharmaceuticals (gemcitabine) (not participating)
  • Teva  UK (docetaxel, exemestane, gemcitabine, paclitaxel, tamoxifen) (not participating)
  • Wockhardt  UK (gemcitabine, paclitaxel, tamoxifen, vinorelbine) (not participating)
  • Zentiva (exemestane) (not participating)

Relevant research groups

  • None

Evidence Review Group

  • Evidence Review Group tbc
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • Tbc

Top


 

Project history

Date Notes
28.8.2013 Guidance published
Top


 

Key documents

This page was last updated: 31 December 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.